VERTEX PHARMACEUTICALS INC / MA
Nasdaq: VRTX·Boston, Massachusetts·CIK 0000875320
- Price
- $537.79
- Base IV
- $266.30
Valuation snapshot
At $537.79, the price is above even our bull case of $442.46.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $266.30
- 50% of the price · range $134.94–$442.46
- Price vs base case
- 102% above
- $537.79 against $266.30
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $134.94 to bull $442.46. Values per share.
Price against each value
- Bear case
- $134.94
- Price 299% above
- No growth
- …
- —
- Base case
- $266.30
- Price 102% above
What does Vertex Pharmaceuticals Inc / Ma do?
Vertex Pharmaceuticals develops and commercializes medicines to treat serious diseases, including cystic fibrosis, sickle cell disease, and various kidney and pain conditions.
It brought in $13B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- Boston, Massachusetts
- Trades on
- Nasdaq as VRTX
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 31¢ was left as profit after every cost, interest and tax. The biggest cost is research and development, 33¢ of every dollar.
- Making what it sells14¢
- Research and development33¢
- Sales, marketing and admin19¢
- Everything else it takes to operate1¢
- Tax6¢
- Left as profit31¢
- Interest and other income came back in+4¢
Who pays Vertex Pharmaceuticals Inc / Ma, and for what?
Vertex is a biotechnology company that discovers, develops and sells prescription medicines for serious diseases. Almost all of its money comes from its cystic fibrosis medicines. It also sells CASGEVY, a one-time gene-editing treatment for two inherited blood disorders, and JOURNAVX, a non-opioid pill for short-term pain.
Vertex sells mainly to specialty pharmacies, distributors and wholesalers (and some treatment centers and hospitals), and the cost is largely paid by government health programs and private insurers.
TRIKAFTA/KAFTRIO
86%Vertex's main cystic fibrosis medicine and by far its biggest product. It treats the underlying cause of the disease in many patients.
TRIKAFTA tabletsJillian Curran, CC BY-SA 4.0, via Wikimedia Commons ALYFTREK
7%A newer cystic fibrosis medicine taken once a day. Vertex expects most people with cystic fibrosis to move to it over time.
Other cystic fibrosis medicines (KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI)
5%Older cystic fibrosis medicines that are still sold alongside the newer ones.
CASGEVY
1%A one-time gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. Vertex shares its profits 60/40 with partner CRISPR Therapeutics. 64 patients received it in 2025.
CASGEVY stem-cell infusion vial · January 2026Image: Gulf News JOURNAVX
1%A non-opioid pill for moderate-to-severe short-term pain in adults. It went on sale in the U.S. in March 2025.
Other revenues
0%Upfront payments from partners Ono and Zai Lab, which licensed the rights to Vertex's kidney drug povetacicept in parts of Asia.
Where its work physically happens, beyond headquarters:
- Jeffrey Leiden Center Campus — Boston, United States. The 617,000-square-foot Leiden I and Leiden II campus expands Vertex's laboratory and clinical-manufacturing capacity for its biologics, cell and genetic therapy pipeline, with Leiden II expected to become operational in late 2026.
- Vertex San Diego Research Site — San Diego, United States. This 170,000-square-foot global research hub is where Vertex discovered three breakthrough cystic-fibrosis medicines, making it central to the scientific franchise that still generates most company revenue.
- Vertex Manufacturing Center — Boston, United States. Vertex's owned 213,000-square-foot continuous-manufacturing facility provides internal clinical and commercial supply capacity and reduces reliance on external manufacturers for selected production steps.
- Lonza Portsmouth T1D Facility — Portsmouth, United States. This dedicated 130,000-square-foot Lonza-operated facility is intended to scale manufacturing for Vertex's type 1 diabetes cell-therapy candidates and support potential commercial production.
- Vertex International Headquarters — London, United Kingdom. Vertex's London international headquarters anchors commercial and administrative operations outside the United States, markets that generated approximately $4.45 billion of 2025 revenue.
How is the business doing?
Sales grew from $6.2B in 2020 to $12B in 2025, about 14% a year.
Running the business leaves about 33¢ of each sales dollar as operating profit, down from 46¢ in 2020.
After paying for its upkeep and new investment, it had $3.2B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Vertex says it exists to use scientific innovation to create medicines that transform the lives of people with serious diseases.
“invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets”
What management says it is working on now:
Extend its lead in cystic fibrosis
Vertex wants to reach more people with cystic fibrosis. It plans to do this through approvals for younger children, more countries agreeing to pay for its medicines, moving patients to ALYFTREK, and developing next-generation treatments.
Vertex Pharmaceuticals 2025 Form 10-KGrow CASGEVY and JOURNAVX
Vertex is working to get more patients treated with CASGEVY through its network of treatment centers. It is also widening insurance coverage and hospital use of JOURNAVX.
Vertex Pharmaceuticals 2025 Form 10-KMove late-stage drugs toward approval
Vertex is running five late-stage programs: povetacicept for two kidney diseases, inaxaplin for APOL1 kidney disease, suzetrigine for diabetic nerve pain, and zimislecel for type 1 diabetes.
Vertex Pharmaceuticals 2025 Form 10-KAdd rare hormone diseases as a fifth area
Vertex bought Crinetics Pharmaceuticals for about $10 billion, completed on September 1, 2026. The deal adds medicines for rare hormone disorders, such as the acromegaly drug PALSONIFY.
Vertex completes acquisition of Crinetics PharmaceuticalsKeep buying and licensing outside science
Alongside its own research, Vertex plans to keep acquiring companies and licensing technologies, as it did with Alpine (povetacicept), Semma (type 1 diabetes) and CRISPR (CASGEVY).
Vertex Pharmaceuticals 2025 Form 10-K
- Total revenue, Full year 2026
- $13.1 billion to $13.2 billion (raised from $12.95–$13.1 billion)
- Vertex Reports Second Quarter 2026 Financial Results
- Revenue from products outside cystic fibrosis, Full year 2026
- $0.5 billion or more
- Vertex Reports Second Quarter 2026 Financial Results
- Combined research, acquired research and selling/admin spending (non-GAAP), Full year 2026 (excludes Crinetics)
- $5.65 billion to $5.75 billion
- Vertex Reports Second Quarter 2026 Financial Results
- Effective tax rate (non-GAAP), Full year 2026
- 19.5% to 20.5%
- Vertex Reports Second Quarter 2026 Financial Results
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 12% more than a year earlier. The year before, quarters averaged 10%.
Its operating margin is narrower than a year ago: 21¢ per sales dollar, against 39¢.
Since Sep 2026 the share price has risen 6%, from $508.34 to $537.79.
Recently
September 30, 2026
Cystic fibrosis revenue, third quarter changed to $3.3B
Vertex Q3 2026 resultsSeptember 30, 2026
GAAP operating margin, third quarter fell to 20.7%
Vertex Q3 2026 resultsJune 30, 2026
CF product revenue, second quarter changed to $3.2B
Vertex Q2 2026 Form 10-Q
Coming up
November 30, 2026
FDA decision on povetacicept for IgA nephropathy
The FDA has accepted Vertex's request for fast-track (accelerated) approval of povetacicept for a serious kidney disease. Approval would give Vertex its first kidney medicine, which would enter a market that already has competing drugs.
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA NephropathyEarly 2027
Early results for inaxaplin in APOL1 kidney disease
Vertex will release a planned early look at its late-stage trial of inaxaplin. The drug could be the first treatment aimed at the cause of this kidney disease.
Vertex Reports Second Quarter 2026 Financial ResultsBy end of 2026
Suzetrigine nerve-pain trials finish enrolling
Vertex expects to finish signing up patients for both late-stage trials of suzetrigine in diabetic nerve pain. This is a step toward a possible second use for the drug sold as JOURNAVX.
Vertex Reports Second Quarter 2026 Financial ResultsSecond half of 2026
Updated type 1 diabetes timelines and other data
Vertex plans to update its timelines for zimislecel and VX-017 in type 1 diabetes. It also plans to share results from VX-670 in myotonic dystrophy and from a mid-stage inaxaplin trial.
Vertex Reports Second Quarter 2026 Financial Results
Our own estimate moved too: the base case went from $350.64 to $266.30 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Heavy reliance on cystic fibrosis
Almost all of Vertex's product sales come from its cystic fibrosis medicines. A competitor, a safety problem, a supply disruption or lower prices for these drugs would hit the whole company.
From the company's own filingsWould hit how fast sales growVertex Pharmaceuticals 2025 Form 10-K
Pressure on drug prices
Governments and insurers in the U.S. and abroad are pushing to lower drug prices. Examples include proposed most-favored-nation pricing rules and state reviews that have looked at TRIKAFTA. Lower prices or less coverage would reduce revenue and profit.
From the company's own filingsWould hit how much of each sale it keepsVertex Pharmaceuticals 2025 Form 10-K
New drugs may fail or sell slowly
Experimental drugs can fail in trials or get turned down by regulators, as happened with VX-264 for type 1 diabetes. Dosing in the zimislecel trial is on hold while Vertex reviews its manufacturing.
From the company's own filingsWould hit how fast sales growVertex Pharmaceuticals 2025 Form 10-K
Costly, complex newer products
CASGEVY costs much more to make, relative to its sales, than the cystic fibrosis pills. Vertex expects its cost of goods to rise as a share of sales in 2026 as sales of these newer products grow.
From the company's own filingsWould hit how much of each sale it keepsVertex Pharmaceuticals 2025 Form 10-K
Royalty dispute over ALYFTREK
Royalty Pharma started an arbitration claiming Vertex owes a royalty of about 8% on ALYFTREK sales, double the 4% Vertex says is due. Losing could raise costs on a drug Vertex expects most patients to switch to.
From the company's own filingsWould hit how much of each sale it keepsVertex Pharmaceuticals 2025 Form 10-K
Safety issues and patent challenges
In 2024 the FDA added a boxed warning about liver injury to TRIKAFTA's label. Separately, others challenge Vertex's patents, and a copy product is being sold in Russia in violation of them.
From the company's own filingsWould hit how fast sales growVertex Pharmaceuticals 2025 Form 10-K
Cystic fibrosis still represented about 0.951 of third-quarter 2026 revenue, so newer medicines have not yet changed the overall sales mix substantially.
From our researchWould hit how fast sales growVertex Q3 2026 results
Third-quarter 2026 research and development expense rose to $1.321 billion from $978 million a year earlier, while selling and administrative expense rose to $844 million from $445 million.
From our researchWould hit how much of each sale it keepsVertex Q3 2026 Form 10-Q
Is it a good business?
From 2016 to 2025 it earned between -10% and 47% on its shareholders' equity, a median of 21%.
Over 10 years its operating margin ranged from 2¢ to 48¢ per sales dollar, a median of 32¢. Gross margin ran from 86¢ to 89¢.
The number of shares grew 6% from 2016 to 2020, so each share owns a smaller slice of the business.
It holds $1.8B more in cash than it owes.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $537.79. Our put its value between $134.94 and $442.46, with $266.30 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $134.94
Sales have recently grown, but this scenario assumes newer medicines gain ground slowly while the costs of developing and selling them stay high.
Base case, $266.30
After recent sales growth, this scenario assumes existing treatments keep growing and newer medicines add enough sales to offset their development costs over time.
Bull case, $442.46
Recent sales growth speeds up in this scenario as newer medicines reach many more patients and profits grow faster than costs.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 102%
For Vertex Pharmaceuticals Inc / Ma to be worth today's $537.79, sales would need to grow about 26.8% a year. We assume 8.8%. Over the last 5 years, sales grew 12.7% a year.
Or, if sales grow 8.8% as we assume, the price works with a profit margin of 73.7% (we assume 36.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 26.8% a year?
Try your own numbersWe're not very sure of this range: it scores 45 out of 100 on our checks. The weakest point is historical stability.
Test the assumptions
Our base value of $266.30 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average8.8%
- Operating margin36.0%
- Long-term growth rate2.2%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$266.30 -50.5%


